Sutro Biopharma price target raised to $35 from $23 at Citizens

Citizens analyst Reni Benjamin raised the firm’s price target on Sutro Biopharma (STRO) to $35 from $23 and keeps an Outperform rating on the shares. The firm continues to believe Sutro shares are undervalued amid the the rapid progress in the clinic, the potential for STRO-004 to report best-in-class efficacy and safety by mid-2026, a growing pipeline of clinical candidates across novel targets, and a solid cash position of $212M, the analyst tells investors in a research note.